This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
TRAM1 / Translocating chain-associated membrane protein 1 · IHC design guide
Design Immunohistochemistry for TRAM1
Plan chromogenic IHC on paraffin sections with the catalog antibody at 0.5–1 μg/ml (datasheet: IHC-P). Colon glandular cells provide a high-staining reference (HPA tissue IHC); assess the observed cytoplasmic and nuclear signal alongside TRAM1’s expected ER membrane location (HPA tissue IHC; UniProt).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
TRAM1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic and nuclear staining (HPA tissue IHC); ER membrane expected (UniProt) | |
| Staining pattern | Cells across tissues: variable cytoplasmic and nuclear staining (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen) | |
| Positive control | Cervix+4 more · see all | |
| Negative control | Fallopian tube+1 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific) | |
| Caveat | IHC staining has low consistency with RNA expression (HPA tissue IHC) | |
| Regulation | Variable staining across tissues (HPA tissue IHC) | |
| Isoform / epitope | 2 isoforms; check epitope position against luminal and cytosolic regions (UniProt) |
Section 1
Recommended TRAM1 IHC & IF Protocols
Compare the catalog antibody’s IHC-P protocol with the published pancreatic tissue microarray protocol (PMC4718295 methods).
| Sample | Tissue sections; selected-image fixative not specified (standard IHC workflow) |
| Fixation | Image fixative and duration unreported (datasheet PA2010); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in citrate buffer, pH 6.0, 20 min at 95–98 °C (standard rule: cytoplasmic / membrane antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-TRAM1, 0.5-1μg/ml (datasheet PA2010) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | TRAM1-positive staining in squamous epithelial cells of cervix (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic and nuclear expression at variable levels in all tissues. No signal in the no-primary control. |
💡Decision noteStart with citrate pH 6.0 retrieval at 95–98 °C for 20 min (page antigen-retrieval rule); the article does not specify retrieval conditions (PMC4718295 methods).
Section 2
What Is the Expected TRAM1 Staining Pattern?
TRAM1 is an ER membrane protein (UniProt Q15629 topology). Epithelial staining varies; HPA rates IHC Approved with low RNA concordance (HPA).
| Colon glandular cells stain strongly (HPA: High). | A cytoplasmic component fits ER localisation (UniProt Q15629; HPA: cytoplasmic). |
| Staining is nuclear only (UniProt: ER membrane). | Review specificity; HPA reports variable nuclear staining but does not establish nuclear TRAM1 (HPA). |
| Prostate glands stain strongly (HPA: Not detected). | Check cross-reactivity or endogenous detection activity (HPA; standard IHC practice). |
| Stain is diffuse across the section. | Suspect background; inspect a no-primary control (standard IHC practice). |
| Colon glands show no signal (HPA: High). | Check the positive control, retrieval and detection (HPA; standard IHC practice). |
💡Expected TRAM1 appearancePositive: high colon gland staining with cytoplasm (HPA: High; cytoplasmic); diffuse stain is suspect (standard IHC practice).
| Epitope position is unspecified; TRAM1 has 8 membrane spans (UniProt topology). | Antibody access may depend on whether its epitope faces cytoplasm or ER lumen (UniProt topology). |
| HPA IHC is Approved, with low RNA concordance (HPA). | Interpret unexpected tissue staining cautiously (HPA: low consistency). |
| IF/ICC: where should signal appear? | ER membrane is expected (UniProt); HPA says Membrane but provides no ICC images (HPA). |
| Situation | Likely cause | Next action |
|---|---|---|
| No colon gland signal (HPA: High). | Retrieval or detection may be inadequate (standard IHC practice). | Check positive control and retrieval conditions (standard IHC practice). |
| Strong prostate gland signal (HPA: Not detected). | Cross-reactivity or endogenous activity is possible (standard IHC practice). | Run no-primary and detection controls (standard IHC practice). |
| Nuclear-only staining (UniProt: ER membrane). | Specificity is uncertain; HPA reports variable nuclear staining (HPA). | Compare cytoplasmic staining and no-primary control (standard IHC practice). |
| Diffuse section-wide stain. | Blocking or detection background is possible (standard IHC practice). | Inspect no-primary control; adjust blocking and washes (standard IHC practice). |
| Uneven stain across a section. | Reagent coverage may be uneven (standard IHC practice). | Inspect section coverage and wash steps (standard IHC practice). |
Experiment evidence
IHC & IF images showing TRAM1 staining
PA2010 · IHCAnti-TRAM1 antibody, PA2010, IHC(P) IHC(P): Human Lung Cancer Tissue
PA2010 · IHCAnti-TRAM1 antibody, PA2010, IHC(P) IHC(P): Rat Kidney Tissue
PA2010 · IFAnti-TRAM1 antibody, PA2010, ICC ICC: HELA Cell
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000067167-TRAM1/tissue/cerebral+cortex#imid_6071376
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000067167-TRAM1/tissue/colon#imid_6071310
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000067167-TRAM1/tissue/liver#imid_6071311
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000067167-TRAM1/tissue/kidney#imid_6071320
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for TRAM1 IHC & IF
🧪Run colon first; its glandular cells should stain for TRAM1 (HPA: Colon glandular cells, High). Run prostate glandular cells as the negative comparison (HPA: Prostate glandular cells, Not detected); on the colon slide, non-glandular cells with background-level staining can serve as internal comparators, but their TRAM1-negative status is unverified by the supplied HPA rows.
Positive control tissue: Cervix (Squamous epithelial cells, HPA High)
Negative control tissue: Fallopian tube (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA carries no ICC-IF cell line for TRAM1; derive a cell-line control from the positive tissue's cell type (Squamous epithelial cells) and confirm it by RNA or western blot first.
Technical controls: Include no-primary (secondary-only), host-species- and isotype-matched controls appropriate to the primary antibody’s clonality, plus a TRAM1 knockout sample or immunizing-peptide block if available (standard IHC specificity controls). For chromogenic IHC, quench endogenous peroxidase and check for endogenous biotin if using avidin–biotin detection (standard IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected PA2010 paraffin-IHC caption does not state a fixative (PA2010 caption: IHC(P), human lung cancer; fixative unreported). Retrieval dependence is unreported, so optimize retrieval empirically for paraffin sections (standard IHC practice). The supplied evidence does not establish that frozen sections or IF are easier, and no colon-specific artefact is reported (HPA: no ICC-IF cell-line images; HPA: Colon glandular cells, High).
HPA tissue IHC evidence for TRAM1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Low consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Cervix | Squamous epithelial cells | High | Protein (IHC) | HPA → |
| Colon | Glandular cells | High | Protein (IHC) | HPA → |
| Duodenum | Glandular cells | High | Protein (IHC) | HPA → |
| Esophagus | Squamous epithelial cells | High | Protein (IHC) | HPA → |
| Oral mucosa | Squamous epithelial cells | High | Protein (IHC) | HPA → |
Section 3
Advanced TRAM1 IHC Tips
Troubleshoot TRAM1 chromogenic IHC in paraffin sections using its ER membrane topology and tissue staining evidence (UniProt Q15629; HPA tissue IHC).
How should I retrieve TRAM1 in paraffin sections when staining is weak?
Start with citrate buffer at pH 6.0, heated to 95–98 °C for 20 min (page retrieval rule: cytoplasmic/membrane antigen). Allow sections to cool in buffer, then compare a retrieved section with a matched section processed without heat to assess whether retrieval improves signal (standard IHC practice). Keep antibody concentration, detection chemistry and development time identical across that comparison so retrieval is the variable under test (standard IHC practice). If staining remains weak, test another retrieval condition on matched sections while monitoring tissue morphology; the supplied evidence does not establish a TRAM1-specific alternative buffer (page retrieval rule; supplied product caption).
Can I infer an optimal fixative for TRAM1 from the tissue images?
No target-specific fixation sensitivity is established here: the PA2010 tissue-IHC caption identifies paraffin processing but does not state the fixative (PA2010 tissue-IHC caption). Record the actual fixative and fixation duration for each specimen, because those details are needed to compare staining across preparation batches (standard IHC practice). When signal differs between batches, stain matched sections together with the same retrieval, antibody incubation and chromogen development before attributing the difference to fixation (standard IHC practice). Do not infer a preferred fixative from variable HPA tissue staining or TRAM1 membrane topology; neither supplies a fixation comparison (HPA tissue IHC; UniProt Q15629 topology).
What staining pattern should I expect, and how should I investigate nuclear signal?
Expect predominantly intracellular, cytoplasmic-pattern staining compatible with an ER membrane protein, rather than a cell-surface outline (UniProt Q15629 subcellular location). HPA reports variable cytoplasmic and nuclear tissue staining, but also reports low consistency between antibody staining and RNA expression (HPA tissue IHC). Inspect nuclear signal separately from cytoplasmic signal in matched sections, using a nuclear counterstain and consistent illumination to locate the staining (standard IHC practice; HPA tissue IHC). If nuclear staining dominates, check a no-primary control and repeat with adjusted antibody concentration before assigning that compartment to TRAM1 (standard IHC practice; UniProt Q15629 subcellular location).
Why might two TRAM1 antibodies stain the same section differently?
TRAM1 has 2 annotated isoforms and 8 transmembrane segments, so an antibody's mapped epitope matters when comparing stains (UniProt Q15629 isoforms and topology). Check whether each immunogen lies in a cytoplasmic loop, a luminal loop or a membrane-spanning region before comparing retrieval results (UniProt Q15629 topology; standard IHC practice). The residue 56 glycosylation site is luminal, while phosphoserine 365 is in a cytoplasmic region; an antibody near either site warrants epitope-specific validation (UniProt Q15629 topology and modifications). If epitope locations are unavailable, compare staining with a second validated antibody or an appropriate specificity control, without assigning discordance to an isoform (standard IHC practice).
How can IF help investigate an ambiguous chromogenic TRAM1 pattern?
Use IF as a separate follow-up to chromogenic IHC, pairing TRAM1 with a marker for the cell type under examination to test which cells carry the signal (standard IF practice). Choose fluorophores after checking tissue autofluorescence in an unstained section, and place the weaker signal in a cleaner spectral channel (standard IF practice). Select permeabilisation according to the antibody's mapped epitope: cytoplasmic and ER-luminal epitopes can require different access conditions because TRAM1 crosses the ER membrane 8 times (UniProt Q15629 topology; standard IF practice). Compare antibody-stained and no-primary images under identical acquisition settings, then assess whether the cellular pattern supports the chromogenic finding (standard IF practice).
How do I reduce diffuse brown staining without losing TRAM1 signal?
Begin with a no-primary control and an appropriate tissue control stained in the same run to distinguish detection background from antibody-dependent signal (standard IHC practice). Block endogenous peroxidase before chromogenic detection, then assess whether the brown product appears without primary antibody; peroxidase blocking and DAB are general IHC steps (standard IHC practice). Titrate the IHC-validated antibody and shorten chromogen development in matched sections while keeping retrieval at citrate pH 6.0 initially (standard IHC practice; page retrieval rule). Evaluate retained cytoplasmic-pattern staining against TRAM1's ER membrane location, and avoid treating uniform extracellular deposit as specific signal (UniProt Q15629 subcellular location; standard IHC practice).
How should I score TRAM1 staining across tissue samples? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and region before scoring, then record the percentage of positive cells and staining intensity for a reproducible H-score (standard IHC practice). An H-score can combine percentages at intensity scores 0–3, giving a possible range of 0–300 when each percentage is multiplied by its score (standard IHC practice). Normalise counts or stained area to evaluable tissue area, such as cells or signal per mm², and exclude necrotic or folded regions (standard IHC practice). Report cytoplasmic and nuclear staining separately because HPA describes both patterns and flags low consistency with RNA expression (HPA tissue IHC).
When is a TRAM1-positive IHC result convincing rather than artefactual?
A convincing result has a reproducible intracellular pattern compatible with TRAM1's ER membrane location and exceeds staining in the no-primary control (UniProt Q15629 subcellular location; standard IHC practice). Interpret the stained cell population explicitly: HPA reports high signal in colon glandular cells, for example, but its tissue IHC has low consistency with RNA expression (HPA tissue IHC). Check section edges and necrotic areas for concentrated chromogen, and check the no-primary control for endogenous enzyme signal before calling focal brown deposits positive (standard IHC practice). Treat isolated strong nuclear staining cautiously because UniProt places TRAM1 at the ER membrane while HPA reports variable nuclear staining (UniProt Q15629 subcellular location; HPA tissue IHC).
Boster reagents
Best TRAM1 / Translocating chain-associated membrane protein 1 IHC Antibodies
PA2010 has IHC images from human paraffin sections and rat paraffin and frozen sections, plus an ICC image from HELA cells (PA2010 image captions). Its listed reactivity is human, mouse and rat (PA2010 catalog).
Real IHC data
Anti-TRAM1 Antibody ®
Cat # PA2010
PA2010 has IHC(P) captions for human lung cancer and rat kidney tissue, and frozen-section IHC captions for rat intestine and brain (PA2010 image captions). Its ICC image is labeled HELA cells; IHC, IHC-F and ICC are listed applications (PA2010 image captions; PA2010 catalog).
Which to pick: Choose PA2010 for paraffin-section IHC based on its human lung cancer and rat kidney IHC(P) captions; the fixative is unreported (PA2010 image captions). For cell staining, PA2010 has an ICC image from HELA cells, but IF is not separately listed as an application (PA2010 ICC caption; PA2010 catalog). It is listed as reactive with human, mouse and rat, though the supplied IHC images show human and rat samples only; its host is rabbit and clonality is unreported (PA2010 catalog; PA2010 image captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q15629 (TRAM1_HUMAN, Translocating chain-associated membrane protein 1).
- Human Protein Atlas. TRAM1 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. TRAM1 subcellular location (ICC-IF): Membrane.
- Human Protein Atlas. TRAM1 antibody validation summary (1 antibodies).
- The Immunohistochemical Evaluation of Solid Pseudopapillary Tumors of the Pancreas and Pancreatic Neuroendocrine Tumors Reveals ERO1Lβ as a New Biomarker. Medicine 2016 — PMC4718295.
- PubMed PMID:1315422 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
- PubMed PMID:16421571 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for TRAM1 (Translocating chain-associated membrane protein 1). Expected localisation Cytoplasmic and nuclear staining (HPA tissue IHC); ER membrane expected (UniProt). Antigen retrieval: Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen). Validated IHC antibody: PA2010 at 0.5-1μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Cervix (Squamous epithelial cells); negative Fallopian tube. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Tissue sections; selected-image fixative not specified (standard IHC workflow); 2. Fixation: Image fixative and duration unreported (datasheet PA2010); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in citrate buffer, pH 6.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-TRAM1, 0.5-1μg/ml (datasheet PA2010); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Caveat: IHC staining has low consistency with RNA expression (HPA tissue IHC); Isoform / epitope: 2 isoforms; check epitope position against luminal and cytosolic regions (UniProt); Regulation: Variable staining across tissues (HPA tissue IHC). Evidence: UniProt Q15629, HPA tissue IHC · Approved, HPA ICC-IF · Membrane, Datasheet PA2010, PMC4718295. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/TRAM1/immunohistochemistry-ihc-guide.